MTMuthukumaran Thulasingam

Muthukumaran Thulasingam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muthukumaran Thulasingam has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Chitra Vellapandian

    SRM Institute of Science and Technology

    3 shared publications
  • Akila E

    1 shared publication
  • Akila Elias

    Departmentof Pharmacognosy, Al-Ameen College of Pharmacy, Bengaluru, 560027, Karnataka, India

    1 shared publication
  • Arik Nabi Shah

    Department of Pharmacy Practice, JSS College of Pharmacy, Mysore, Karnataka

    1 shared publication
  • Asok Kumar K

    Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, Coimbatore

    1 shared publication
  • Asok Kumar Kuppusamy

    Department of Pharmacology, College of Pharmacy, Sri Ramakrishna Institute of Paramedical Sciences, The Tamil Nadu Dr. M.G.R Medical University, Coimbatore, 6410144, Tamil Nadu, India

    1 shared publication

Latest Publications

  • Design and Computational Evaluation of Isatin Derivatives as Dual MAO-A/IDO1 Inhibitors: Molecular Docking and Molecular Dynamics Insights

    by Muthukumaran Thulasingam, Chitra Vellapandian

    Background: Monoamine oxidase-A (MAO-A) and indoleamine 2,3- dioxygenase-1 (IDO1) contribute to major depressive disorder via monoamine depletion and activation of the kynurenine pathway. Dual inhibition of these enzymes represents a rational multitarget therapeutic strategy. Objective: To identify potent dual MAO-A/IDO1 inhibitors from a focused library of isatin derivatives using an integrated computational approach. results: Several derivatives demonstrated improved docking scores and favorable interactions within the catalytic pockets of both targets. SDI-107 and SDI-113 maintained stable binding conformations during 100 ns simulations, with protein backbone deviations within ~2–2.5 Å, limited active-site residue fluctuations, sustained hydrogen bonding, and favorable binding free energy profiles compared to moclobemide. Methods: A total of 140 isatin derivatives were screened against MAO-A (PDB ID: 2BXR) and IDO1 (PDB ID: 6E35) using AutoDock 4.2. Top-ranked candidates were subjected to 100 ns molecular dynamics simulations using the Desmond module. Complex stability was evaluated through root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (rGyr), and solvent-accessible surface area (SASA) analyses to assess the structural stability and dynamic behavior of the protein– ligand complexes throughout the 100 ns molecular dynamics simulations. Moclobemide was used as the reference inhibitor. Results: Several derivatives demonstrated improved docking scores and favorable interactions within the catalytic pockets of both targets. SDI-107 and SDI-113 maintained stable binding conformations during 100 ns simulations, with protein backbone deviations within 2.0 to 2.5 Å, limited active-site residue fluctuations, sustained hydrogen bonding, and favorable binding free energy profiles compared with moclobemide. Discussion: The combined docking and molecular dynamics analyses indicate that structural stability and persistent intermolecular interactions underpin the dual inhibitory potential of SDI-107 and SDI-113. The isatin scaffold appears well suited for simultaneous engagement of the catalytic environments of MAO-A and IDO1, supporting its potential as a multitarget pharmacophore for antidepressant drug discovery. Conclusion: SDI-107 and SDI-113 emerged as promising dual MAO-A/IDO1 inhibitors, demonstrating favorable binding affinity, stable protein–ligand interactions, and encouraging binding free energy profiles. These findings support further experimental validation and structural optimization toward the development of multitarget-directed antidepressant agents.

  • Emerging Biomarkers and Therapeutic Targets in Major Depressive Disorder: Mechanistic Insights and Clinical Perspectives

    by Muthukumaran Thulasingam, Chitra Vellapandian

    Major depressive disorder (MDD) affects over 280 million people worldwide and is associated with functional disability, reduced productivity, and impaired quality of life. Despite extensive research, its etiology and management remain complex and multi-factorial. This review critically examines contemporary etiological hypotheses, emerging biomarkers, and recent therapeutic advancements in MDD. A systematic search of PubMed, Embase, Scopus, and PsycINFO databases identified English-language studies relevant to pathophysiology and treatment. Stress-related mechanisms, including hyperactivity of the hypothalamic–pituitary–adrenal (HPA) axis, elevated cortisol, and dysregulated inflammatory cytokines (e.g., IL-6, TNF-α), are consistently implicated. Neuroimaging and proteomic studies reveal structural and functional alterations in the prefrontal cortex, hippocampus, and amygdala, while genetic polymorphisms (e.g., BDNF Val66Met) are associated with susceptibility. Therapeutically, rapid-acting antidepressants such as ketamine achieve 50-70% response rates within 24 hours, compared with 30-40% for conventional SSRIs over 4-6 weeks. Non-pharmacological approaches, including cognitive-behavioral therapy and mindfulness-based interventions, show remission rates of 30-50% in moderate-to-severe depression. The integration of biomarker research with innovative treatments highlights the potential for personalized, patient-centered care. Future studies should focus on large-scale biomarker validation and the development of tailored therapeutic algorithms to optimize outcomes in MDD.

  • Polyphenols and Flavanoids

    by Muthukumaran Thulasingam, Chitra Vellapandian, Satheeshkumar Sellamuthu, Mythreyi R. Rajendran, Priya Dharshini Shanmugam

    Diabetes and obesity are the main causes of wounds which are regarded as a major issue that impacts the healthcare industry in many nations. Unhealthy lifestyle choices and behaviors exacerbate wounds. After an injury, wound healing is a complex physiological process that is necessary to restore the epithelial barrier. Because of their well-known anti-inflammatory, angiogenesis, re-epithelialization, and antioxidant actions, polyphenols and flavonoids have been shown in numerous studies to have wound-healing capabilities. They have potent anti-inflammatory, antibacterial, and antioxidant qualities and are mostly found in fruits, vegetables, tea, and wine. The complex molecular processes by which polyphenols and flavonoids influence wound healing include immune response modulation, collagen synthesis enhancement, oxidative stress reduction, and angiogenesis promotion. Additionally, the NF-κB and MAPK pathways, two important signaling pathways involved in tissue repair and inflammatory regulation, are influenced by these chemicals. According to research, flavonoids and polyphenols may also support angiogenesis, the process of forming new blood vessels, and extracellular matrix remodeling, both of which are essential for proper wound closure and healing. This chapter provides a comprehensive review of the most current studies on the role of flavonoids and polyphenols in wound healing, with a focus on the potential therapeutic applications of these substances to enhance wound care and prevent chronic wounds.To determine the usefulness of polyphenols and flavonoids in therapeutic settings, more clinical research is necessary to examine their pharmacological characteristics and safety profiles.

  • Enhancing Bioavailability: A Review of Solubilization Techniques for Low-Soluble Drugs

    by Muthukumaran Thulasingam, Gomathi Jeganathan, Farzana Affrin Mohammed Farooq, Sandhiya Vaithi, Sunil Kumar Kadiri, Rajesh Kumar Sharma, Asok Kumar Kuppusamy, Lakshmi Kanakaraj, Shri Vijaya Kirubha T

    Poor aqueous solubility is a major barrier in drug development, affecting bioavailability, therapeutic efficacy, and formulation design. Estimates suggest that 70–90% of drug candidates and nearly 40% of marketed drugs exhibit limited solubility. This review examines both conventional and advanced approaches for solubility enhancement. Traditional strategies such as particle size reduction, salt formation, prodrug design, and solid dispersion have demonstrated measurable improvements, though challenges with stability, scalability, and reproducibility persist. In recent years, nanotechnology-based systems, including nanoparticles, liposomes, dendrimers, and metalorganic frameworks (MOFs), have emerged as promising platforms, offering superior solubility and bioavailability. However, these approaches face practical limitations in large-scale manufacturing and regulatory approval. Artificial intelligence (AI) contributes by predicting solubility behavior and streamlining formulation optimization, thereby complementing experimental strategies. Together, these innovations represent a shift toward more efficient and precise drug development. Improving solubility is not only critical for reducing dose requirements but also for enhancing patient adherence and clinical outcomes. The integration of nanotechnology with AI-based models provides a forward-looking path for overcoming current barriers in oral drug delivery. Future research should focus on addressing issues of cost-effectiveness, regulatory harmonization, and commercial scalability to ensure that these approaches translate successfully into clinical practice.

  • Exploring New Frontiers in Pharmacological Treatment of Depression: A Review on Recent Advances

    by Muthukumaran Thulasingam, Chitra Vellapandian

    The current treatment strategy is still subpar, especially for severe mental problems, despite tremendous progress in the understanding of the central nervous system. Improving healthcare usually entails two main approaches: investigating new treatment approaches and improving current ones. New pharmacological options include enhanced monoaminergic pharmaceuticals, old treatments reassessed with a better knowledge of the biology of mental disease, and medications that target new therapeutic pathways. One major clinical challenge in the treatment of depression is resistance to antidepressant drugs. It appears promising to switch to monotherapy using new multifunctional antidepressants and add new atypical antipsychotics, such as brexpiprazole and aripiprazole. Current efforts are concentrated on unraveling depression's origins and pinpointing fresh targets for pharmacological intervention. This review explores encouraging novel pharmacological avenues for major depressive disorder treatment. These include targeting receptors, such as N-methyl-D-aspartate and metabotropic glutamate receptors, and employing glutamatergic modulators and various augmentation strategies, all of which hold the potential for reversal of depressant effects. Combining innovative concepts with enhancements of existing discoveries may propel antidepressant research forward, offering hope for developing compounds that are effective and rapid in their action, even among patients who have found limited success with other therapies.


  • Anthelmintic Effect of Biosynthesized Silver Nanoparticles of the Momordica dioica Fruit Extract

    by Pruthvi Nagaraj, Muthukumaran Thulasingam, Akila Elias, Pawan Kumar Gurung, Vontoor Byrappa Narayanaswamy, Pruthvi N, Akila E

    Background: Momordica dioica belongs to the family Cucurbitaceae and is generally known as teasle gourd or spiny gourd. This plant is highly significant for its active phytoconstituents bearing several pharmacological activities. Objectives: This study aims to evaluate the anthelmintic activity of biosynthesized Silver nanoparticles of Momordica dioica fruit extract against Pheretima Posthuma. Methods: Momordica dioica silver nanoparticles were prepared by green synthesis and were characterized using spectroscopic methods like UV-visible, FTIR, and Scanning Electron Microscopy (SEM) techniques. The prepared silver nanoparticles were investigated for the targeted activity using Albendazole as standard and normal saline as the control. Results: The UV-visible spectrophotometer showed absorbance in the range of 424 nm. FTIR revealed the presence of functional groups of both extract and nanoparticles. The spherical shape of the AgNPs and their size ranges below 100 nm by SEM. The In-vitro anthelmintic activity showed the paralysis and mortality rate of the worms for the fruit extract, and silver nanoparticles were found to be 45.03±0.1, 60.13±0.1, and 12.35±0.04, 22.34±0.02 by One way ANOVA (p <0.0001). Conclusion: The fruit extract converted to silver nanoparticles had better anthelmintic activity compared to the fruit extract. The paralysis and death time were reduced 4 to 5 times, which showed the improved effect of the silver nanoparticles of Momordica dioica extract.


  • Green Synthesis and Characterization of Silver Nanoparticles from Vernonia cinerea: Antioxidant and Anticancer Activities in Colorectal Cancer (Caco-2) Cells

    by Shaik Sadik, Vasia Tamreen, Muthukumaran Thulasingam, Laxmesh Narasimhamurthy, Sandipan Jana, Bharath Ramamurthy, Jeswanth Yadav Kammaganahalli Mallesh, Surat Jamal Sheikh, Nagaraja Sreeharsha, Arik Nabi Shah

    Introduction: Silver nanoparticles (AgNPs) have been widely studied for their antioxidant and anticancer properties. Vernonia cinerea has demonstrated significant antitumor activity, particularly in inhibiting the growth of colorectal cancer cells. This study aims to synthesize silver nanoparticles using Vernonia cinerea leaf extract and evaluate their antioxidant and anticancer efficacy against colorectal cancer cell lines. Methods: AgNPs were synthesized via the combustion method using Vernonia cinerea leaf extract. The nanoparticles were characterized for their physico-chemical and morphological properties using Fourier Transform Infrared Spectroscopy (FTIR), Scanning Electron Microscopy (SEM), UV-visible spectrophotometry (UV-Vis), and X-Ray Diffraction (XRD) analysis. Antioxidant activity was assessed using the DPPH assay, and anticancer potential was evaluated through cytotoxicity assays on CaCo2 colorectal cancer cells using varying concentrations of AgNO₀. Results: FTIR analysis revealed characteristic absorption bands at 664, 605, 557, 531, and 513 cm⁸¹, confirming the formation of silver ion-bound nanoparticles. XRD analysis showed Bragg’s reflections at 38.066°, 31.59°, 37.56°, 53.01°, 64.93°, and 76.27°, indicating crystalline structure. Elemental analysis confirmed a 60% silver ion composition. The synthesized AgNPs exhibited dose-dependent antioxidant activity and significant cytotoxic effects against CaCo2 cells. Discussion: The incorporation of Vernonia cinerea extract into AgNPs enhanced the stability and biological activity of the nanoparticles. The observed anticancer effects support previous findings on the therapeutic potential of both AgNPs and Vernonia cinerea. Limitations include the need for in vivo studies to confirm these results. result: The absorption bands at 664 cm-1, 605 cm-1, 557 cm-1, 531 cm-1, and 513 cm-1 in the FTIR range of Vernonia Cinerea (VC) AgNP’s demonstrated the formation of silver ion-bounded nanoparticles of the VC extract. These results indicate that AgNP’s coated with Vernonia have several characteristics that enhance their stability. The diffraction of the X-ray spectrum of the produced AgNP’s showed the Braggs reflections in the XRD pattern 38.066, 31.59, 37.56, 53.01, 64.93, and 76.27. The sample's elemental composition was determined through elemental analysis, with 60% silver ions. After conducting antioxidant investigations on AgNP concentrations using the DPPH assay, the study conducted a cell-based cytotoxic experiment using different doses of AgNO3. Conclusion: Synthesized silver nanoparticles using Vernonia cinerea exhibit strong antioxidant activity and significant anticancer effects, reducing CaCo2 cell proliferation and motility. These findings support their potential as therapeutic agents in the treatment of colorectal cancer.

  • Docking, Synthesis, and In vitro Anti-depressant Activity of Certain Isatin Derivatives

    by Asok Kumar K, Thulasingam Muthukumaran, Francis M Saleshier

    Background: In vitro, the molecular docking method has been suggested for estimating the biological affinity of the pharmacophores with physiologically active compounds. It is the latter stage in molecular docking, and the docking scores are examined using the AutoDock 4.2 tool program. The chosen compounds can be evaluated for in vitro activity based on the binding scores, and the IC50 values can be computed. Objective: The purpose of this work was to create methyl isatin compounds as potential antidepressants, compute physicochemical characteristics, and carry out docking analysis. Methods: The protein data bank of the RCSB (Research Collaboratory for Structural Bioinformatics) was used to download the PDB structures of monoamine oxidase (PDB ID: 2BXR) and indoleamine 2,3-dioxygenase (PDB ID: 6E35). Based on the literature, methyl isatin derivatives were chosen as the lead chemicals. By determining their IC50 values, the chosen compounds were tested for in vitro anti-depressant activity. Results: The binding scores for the interactions of SDI 1 and SD 2 with indoleamine 2,3 dioxygenase were found to be -10.55 kcal/mol and -11.08 kcal/mol, respectively, while the scores for their interactions with monoamine oxidase were found to be -8.76 kcal/mol and -9.28 kcal/mol, respectively, using AutoDock 4.2. The relationship between biological affinity and pharmacophore electrical structure was examined using the docking technique. The chosen compounds were tested for their ability to inhibit MAO, and the IC50 values for each were found to be 51.20 and 56, respectively. Conclusion: This investigation has identified many novel and effective MAO-A inhibitors from the family of chemicals known as methyl isatin derivatives. Lead optimization was applied to the SDI 1 and SDI 2 derivatives. The superior bioactivity, pharmacokinetic profile, BBB penetration, pre-ADMET profiles, such as HIA (human intestinal absorption) and MDCK (Madin-Darby canine kidney), plasma protein binding, toxicity assessment, and docking outcomes, have been obtained. According to the study, synthesised isatin 1 and SDI 2 derivatives exhibited a stronger MAO inhibitory activity and effective binding energy, which may help prevent stress-induced depression and other neurodegenerative disorders caused by a monoamine imbalance.